Stay updated on PLACARD Trial: CXD101 + Pembrolizumab in DLBCL

Sign up to get notified when there's something new on the PLACARD Trial: CXD101 + Pembrolizumab in DLBCL page.
Latest website image capture
Clouds background image

Latest updates to the PLACARD Trial: CXD101 + Pembrolizumab in DLBCL page

  1. Check
    today
    Change Detected
    Summary
    The web page has undergone significant changes, including the addition of new medical terms and disease classifications related to diffuse large B-cell lymphoma, while also removing several related terms and location details.
    Difference
    4%
    Check dated 2025-08-30T11:11:56.000Z thumbnail image
  2. Check
    7 days ago
    No Change Detected
  3. Check
    14 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.11 to version 2.16.12.
    Difference
    0.1%
    Check dated 2025-08-16T04:25:25.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The web page has been updated from version v2.16.10 to v2.16.11.
    Difference
    0.1%
    Check dated 2025-08-08T23:48:29.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.
    Difference
    1.0%
    Check dated 2025-08-01T19:18:22.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.16.6 to v2.16.8 and added a section on HHS Vulnerability Disclosure.
    Difference
    0.2%
    Check dated 2025-07-25T14:34:07.000Z thumbnail image
  7. Check
    43 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.5 to version 2.16.6.
    Difference
    0.1%
    Check dated 2025-07-18T11:30:14.000Z thumbnail image

Stay in the know with updates to PLACARD Trial: CXD101 + Pembrolizumab in DLBCL

Enter your email address, and we'll notify you when there's something new on the PLACARD Trial: CXD101 + Pembrolizumab in DLBCL page.